Femasys INC 8-K filings

Femasys Inc. announced the closing of a $30 million private placement of common stock and warrants, strengthening its financial position and providing capital for future operations.

Femasys Inc. shareholders elected two Class II directors and ratified the appointment of KPMG LLP as the independent auditor at the 2026 Annual Meeting.

Femasys Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement following a 1-for-20 reverse stock split.

Femasys Inc. has implemented a 1-for-20 reverse stock split of its common stock, effective June 5, 2026.

Femasys Inc. will implement a 1-for-20 reverse stock split, effective June 5, 2026, with trading on a split-adjusted basis commencing June 8, 2026.

Femasys Inc. details its multi-asset portfolio and commercialization strategy targeting large, underserved markets in fertility and permanent birth control.

Femasys reports Q1 2026 revenue growth and progress in its fertility and permanent birth control product pipelines.

Femasys Inc. held a special meeting on April 29, 2026, where stockholders approved a reverse stock split and the issuance of shares related to convertible notes and warrants.

Femasys Inc. announced the appointment of John Canning as Chief Operating Officer, effective March 30, 2026, to bolster operational execution and commercial expansion.

Femasys Inc. announced its financial results for the year ended December 31, 2025, reporting increased sales and significant progress in its FemBloc and FemaSeed product lines.

Femasys Inc. announced amendments to its outstanding notes and warrants, issued new Series D-1 Warrants, and appointed Kenneth D. Eichenbaum, M.D., M.S.E. to its Board of Directors.

Femasys Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, pushing the deadline to July 13, 2026.

Femasys Inc. announced a prospectus supplement for an "at-the-market" offering of up to $9.8 million in common stock.

Femasys Inc. announced it has received U.S. FDA 510(k) clearance for its next-generation FemVue Controlled diagnostic device, integrating existing technologies for enhanced fallopian tube evaluation.

Femasys Inc. reported increased sales and reduced net loss in Q3 2025, driven by FemBloc commercialization and strategic financing, while advancing its U.S. regulatory pathway.

Femasys Inc. announced a significant initial order for its FemBloc permanent birth control solution, expanding its presence in France and the Benelux region.

Femasys Inc. has entered into a $12 million private placement of senior secured convertible notes and warrants to repay existing debt and fund working capital, with significant insider participation.

Femasys Inc. announced FDA approval to advance the final phase of its FemBloc trial and secured $12 million in financing, with potential to reach $58 million.

Femasys Inc. believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement, averting a potential delisting after a recent $8.0 million capital raise and warrant exercises.

Femasys Inc. announced that Chief Operating Officer Daniel Currie will retire effective December 15, 2025, after more than 20 years of service.

Femasys Inc. announced an underwritten public offering of common stock and warrants, expected to raise $8.0 million in gross proceeds to fund commercial expansion and product development.

Femasys Inc. announced it received UK regulatory approval for its FemBloc Permanent Birth Control, advancing its European commercialization strategy.

Femasys Inc. announced Q2 2025 financial results, highlighting key regulatory approvals and commercialization progress for its fertility and birth control solutions.

Femasys Inc. announced its first commercial entry into Europe with an approximately $400,000 USD order for FemBloc Permanent Birth Control in Spain, marking a strategic milestone in global expansion.

Femasys Inc. has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting if not resolved by January 12, 2026.

Femasys Inc. has entered into an Any Market Purchase Agreement with Alumni Capital LP, providing the company with the right to sell up to $10 million of its common stock through a series of flexible purchases.

Femasys Inc. announced regulatory approvals in Australia and New Zealand for its FemaSeed first-line infertility treatment and FemVue diagnostic, expanding its global market reach.

Femasys Inc. announced that its stockholders approved the election of two Class I directors, an amendment to its 2021 Equity Incentive Plan to increase authorized shares, and the ratification of KPMG LLP as its independent auditor at the Annual Meeting held on June 25, 2025.

Femasys Inc. announced it has received European CE mark approval for its FemBloc System, the first non-surgical permanent birth control solution, marking a significant global regulatory milestone.

Femasys Inc. announced the appointment of Kelley Nicholas as Chief Commercial Officer, tasked with driving revenue growth and expanding the company's global presence, particularly for its fertility and women's health product portfolio.